ANDA 40730, held by Rising. Hydralazine Hydrochloride.
As of Nov 16, 2026, ANDA 40730 (Hydralazine Hydrochloride), held by Rising, was first approved by FDA on Apr 21, 2009, with 2 approved supplements and 0 published complete response letters.
Indications & Usage Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydralazine Hydrochloride20MG/ML · injectable;injection | Hydralazine Hydrochloride | Rx |
| Mar 9, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 7, 2015 | Supplement 2Labeling | Approved | None posted |
| Apr 21, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters